Abstract
Rett syndrome (RTT) is one of a group of neurodevelopmental disorders typically characterized by deficits in the X-linked gene MECP2 (methyl-CpG binding protein 2). The MECP2 gene encodes a multifunctional protein involved in transcriptional repression, transcriptional activation, chromatin remodeling, and RNA splicing. Genetic deletion of Mecp2 in mice revealed neuronal disabilities including RTT-like phenotypes and provided an excellent platform for understanding the pathogenesis of RTT. So far, there are no effective pharmacological treatments for RTT because the role of MECP2 in RTT is incompletely understood. Recently, human induced pluripotent stem cell (hiPSC) technologies have improved our knowledge of neurological and neurodevelopmental diseases including RTT because neurons derived from RTT-hiPSCs can be used for disease modeling to understand RTT phenotypes and to perform high throughput pharmaceutical drug screening. In this review, we provide an overview of RTT, including MeCP2 function and mouse models of RTT. In addition, we introduce recent advances in disease modeling of RTT using hiPSC-derived neural cells.
| Original language | English |
|---|---|
| Pages (from-to) | 544-550 |
| Number of pages | 7 |
| Journal | CNS and Neurological Disorders - Drug Targets |
| Volume | 15 |
| Issue number | 5 |
| Publication status | Published - 2016 May 1 |
Keywords
- Autism
- Drug screening
- Human induced pluripotent stem cells (hiPSCs)
- Methyl-CpG binding protein 2 (MeCP2)
- Neural differentiation
- Rett syndrome
ASJC Scopus subject areas
- Neuroscience(all)
- Pharmacology
